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How intracellular cytoskeletal and signaling proteins
connect and communicate with the extracellular matrix
(ECM) is a fundamental question in cell biology. Recent
 
biochemical, cell biological, and genetic studies have
revealed important roles of cytoplasmic integrin-linked
kinase (ILK) and its interactive proteins in these processes.
 
Cell adhesion to ECM is an important process that controls
cell shape change, migration, proliferation, survival, and
differentiation. Upon adhesion to ECM, integrins and a
selective group of cytoskeletal and signaling proteins are
recruited to cell matrix contact sites where they link the
actin cytoskeleton to the ECM and mediate signal trans-
duction between the intracellular and extracellular
compartments. In this review, we discuss the molecular
activities and cellular functions of ILK, a protein that is
emerging as a key component of the cell–ECM adhesion
structures.
Integrin-linked kinase–binding proteins
 
Integrin-linked kinase (ILK)* was identified and cloned 6 yr
ago based on its interaction with the 
 
 
 
1 integrin cytoplasmic
 
domain (Hannigan et al., 1996). It comprises three structurally
distinct regions (Fig. 1). Four ANK repeats lie at the NH
 
2
 
terminus of ILK. COOH-terminal to the ANK domain is a
pleckstrin homology (PH)-like motif. Further downstream
and partially overlapping with the PH-like motif is the
COOH-terminal domain, which exhibits significant homology
to other protein kinase catalytic domains. One of the key
functions of ILK is to mediate protein–protein interactions.
To date, nine different ILK-binding proteins have been
identified (Table I).
The interaction between ILK and PINCH, a focal adhesion
protein comprised primarily of five LIM domains (Wu,
1999), has been studied in detail. ILK forms a complex with
PINCH through direct binding of the ILK NH
 
2
 
-terminal
ANK domain to the second zinc finger located within the
LIM1 domain of PINCH (Li et al., 1999; Tu et al., 1999).
Structural studies have revealed that many residues in this
zinc finger undergo large chemical shift changes upon ILK
binding (Velyvis et al., 2001), suggesting that the interaction
likely involves a conformational change of the LIM1 domain.
The COOH-terminal domain of ILK interacts with the
 
 
 
1 integrin cytoplasmic domain (Hannigan et al., 1996)
and at least three different cytoplasmic adaptor proteins.
CH-ILKBP, which contains two calponin homology (CH)
domains, was identified and cloned in a yeast two-hybrid
screen of a human cDNA library using the ILK COOH-ter-
minal domain as bait (Tu et al., 2001). The CH2 domain of
CH-ILKBP mediates the interaction with ILK (Tu et al.,
2001). Two proteins (actopaxin [Nikolopoulos and Turner,
 
2000] and 
 
 
 
-parvin [Olski et al., 2001]) that are closely
related structurally to human CH-ILKBP have been identi-
fied independently and cloned from rat and mouse cDNA
libraries, respectively. Interestingly, actopaxin was identified
in a search for proteins that bind to the LD1 motif of paxil-
lin (Nikolopoulos and Turner, 2000), and 
 
 
 
-parvin was
identified based on its sequence homology with the actin-
binding domain of 
 
 
 
-actinin (Olski et al., 2001). Although
murine actopaxin and 
 
 
 
-parvin were identified based on
binding activities toward proteins other than ILK, the high
degree of sequence similarity of CH-ILKBP, actopaxin, and
 
 
 
-parvin at both the protein level (98% identical) and the
cDNA level (90% identical) suggest that the human, rat,
and mouse proteins are orthologues and therefore are likely
to share the ILK-binding activity. In an independent study,
Yamaji et al. (2001) identified and cloned another human
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protein, affixin, that also binds to the ILK COOH-terminal
domain. CH-ILKBP and affixin are encoded by two differ-
ent genes, but they share significant sequence similarity, par-
ticularly in the CH2 domains that mediate the ILK binding,
suggesting that they likely recognize a common site on ILK.
Affixin is the human orthologue of mouse 
 
 
 
-parvin, another
recently described actin-binding protein (Olski et al., 2001).
These recent studies define a new family of ILK-binding
proteins that include CH-ILKBP–actopaxin–
 
 
 
-parvin and
affixin–
 
 
 
-parvin. In addition to interacting with the CH2
domains of CH-ILKBP–actopaxin–
 
 
 
-parvin and affixin–
 
 
 
-parvin, the ILK COOH-terminal domain can also be rec-
ognized by the paxillin LD1 motif (Nikolopoulos and
Turner, 2001).
Some, although probably not all, of the interactions de-
scribed above occur simultaneously in cells. It has been dem-
onstrated recently that ILK binds to PINCH and CH-
ILKBP simultaneously through two separate domains (the
NH
 
2
 
-terminal ANK domain and the COOH-terminal ki-
nase domain), resulting in the formation of a multicompo-
nent PINCH–ILK–CH-ILKBP complex in cells (Tu et al.,
2001). On the other hand, paxillin was not detected as part
of the multicomponent ILK complex, despite its ability to
interact with both ILK and CH-ILKBP through the LD1
motif.
 
Localization of ILK to cell matrix contact sites
 
The interactions of mammalian cells with extracellular ma-
trix (ECM) are mediated by molecularly and morphologi-
cally distinct structures, among which the best characterized
are focal adhesions (Burridge and Chrzanowska-Wodnicka,
1996) and fibrillar adhesions (or ECM contacts) (Zamir et
al., 1999). ILK localizes to both focal adhesions (Hannigan
et al., 1996; Li et al., 1999; Mulrooney et al., 2000; Nikol-
opoulos and Turner, 2001) and fibrillar adhesions (Guo et
al., 2001), which is consistent with a role of ILK in cell ad-
hesion, spreading, and fibronectin matrix assembly (Hanni-
gan et al., 1996; Wu et al., 1998; Tu et al., 2001). The local-
ization of ILK to these adhesion sites is mediated by at least
two interactions. Mutations in the ILK NH
 
2
 
-terminal do-
main that disrupt the PINCH binding impair the ability of
ILK to localize to these sites, indicating that the PINCH
binding is required in this process (Li et al., 1999). How-
ever, PINCH binding is not sufficient, since deletion of the
ILK COOH-terminal domain also abolishes the localization
of ILK to these sites (Li et al., 1999). Because the ILK
Figure 1. ILK interactions and ILK-
mediated signaling pathways. (A) This 
figure depicts the interaction of ILK with 
various proteins many of which, includ-
ing ILK, are found at sites of integrin 
connections to the actin cytoskeleton. ILK 
can anchor to integrins by interacting 
with the cytoplasmic domain of certain   
integrin subunits. The NH2-terminal 
ankyrin repeats mediate interactions with 
ILKAP, a PP2C phosphatase, which 
negatively regulates ILK signaling, and 
PINCH, a LIM domain–only protein, 
which potentially couples ILK to growth 
factor receptors and PI 3-kinase by 
binding to another adaptor protein, 
Nck-2. PINCH is also required for the 
localization of ILK to cell adhesion sites 
and can be found in a stable complex 
with ILK and another ILK-binding protein, 
CH-ILKBP. The latter binds to ILK at its 
COOH terminus, which comprises the 
kinase domain. A closely related protein, 
affixin, binds to ILK in the same region, as does paxillin, via its LD1 domain. 
CH-ILKBP, paxillin, and probably other ILK-binding proteins can bind directly 
or indirectly to actin filaments, thus coupling integrins to the actin cytoskeleton 
via ILK. Signaling proteins, PKB, PDK-1, and GSK-3 can also interact with ILK, 
and ILK can phosphorylate PKB and GSK-3. Affixin is also a substrate of ILK, and 
the kinase activity of ILK appears to be involved in enhancing the ability of the 
affixin CH2 domain to inhibit cell spreading. (B) Signaling pathways activated 
by ILK. PTEN and ILKAP negatively regulate ILK activation. Activated ILK can 
directly phosphorylate PKB/Akt and GSK-3. Phosphorylation of PKB/Akt by ILK 
contributes to its activation, leading to suppression of apoptosis and anoikis. 
Phosphorylation of GSK-3 results in its inhibition, leading to stabilization of 
 -catenin and stimulation of AP-1 activity.  -catenin and CREB activation via 
ILK and GSK-3 contribute to the upregulation of cyclin D1, whereas AP-1 
activation leads to stimulation of matrix metalloproteinase-9 expression. ILK is 
also involved in regulating Erk, since overexpression of ILK prevents Erk 
inactivation during myogenic differentiation. ILK can also directly phosphorylate 
MLC in a calcium-independent manner, thus potentially regulating smooth 
muscle contraction and possibly cell motility in nonmuscle cells. 
ILK and its interactors |
 
 Wu and Dedhar 507
 
COOH-terminal domain mediates interactions with multi-
ple proteins, including integrins, CH-ILKBP–actopaxin–
 
 
 
-parvin, affixin–
 
 
 
-parvin, and paxillin, the requirement of
the ILK COOH-terminal domain likely reflects the need of
one or more of these interactions. Mutations in an ILK
COOH-terminal sequence that is 15–33% identical to the
paxillin-binding sequences in vinculin, FAK, and actopaxin,
disrupt the focal adhesion localization of ILK, supporting a
role of paxillin in this process (Nikolopoulos and Turner,
2001). However, because paxillin is deficient in fibrillar ad-
hesions (Zamir et al., 1999) other ILK COOH-terminal–
binding proteins are likely required in the targeting of ILK
to the cell matrix contact sites.
 
A crucial role of ILK in anchoring the actin filaments to 
cell matrix contact sites
 
In genetic model systems such as 
 
Drosophila
 
 and 
 
Caenorhab-
ditis elegans
 
, null mutations of ILK cause defects similar to
loss of integrin function (Zervas et al., 2001) (Mackinnon,
A.C., and B.D. Williams. 2000. 40th American Society for
Cell Biology Annual Meeting. 2664 [Abstr.]). Closer exami-
nation of 
 
ilk
 
-null mutants in 
 
Drosophila
 
 has revealed that ac-
tin filaments are detached from the membranes at the mus-
cle attachment sites (Zervas et al., 2001). Several lines of
evidence suggest that CH-ILKBP–actopaxin–
 
 
 
-parvin func-
tions as one of the key bridge molecules, linking ILK to the
actin filaments. First, CH-ILKBP–actopaxin–
 
 
 
-parvin can
interact with not only ILK but also actin (Nikolopoulos and
Turner, 2000; Olski et al., 2001; Tu et al., 2001). Second,
overexpression of an ILK-binding CH2 fragment of CH-
ILKBP–actopaxin–
 
 
 
-parvin in cells inhibits the actin stress
fiber formation and cell shape change (Nikolopoulos and
Turner, 2000; Tu et al., 2001). Third, mutants of the 
 
C. ele-
gans
 
 homologue of CH-ILKBP–actopaxin–
 
 
 
-parvin like
those of 
 
C. elegans
 
 ILK display defects in the assembly of
muscle dense bodies that attach actin filaments to sarco-
lemma (Lin, X., and B.S. Williams. 2000. 40th American
Society for Cell Biology Annual Meeting. 2666 [Abstr.]).
Are there other linkages between ILK and the actin cy-
toskeleton? The answer is almost certainly yes. One poten-
tially important connection could be provided by PINCH.
In 
 
C. elegans
 
, PINCH like ILK is required for the assembly
of muscle-dense bodies (Hobert et al., 1999). Paxillin can
interact with ILK and actin-binding proteins, including vi-
culin and CH-ILKBP–actopaxin–
 
 
 
-parvin, and therefore
could provide another linkage to the actin filaments. An ad-
ditional connection could be provided by affixin–
 
 
 
-parvin.
Overexpression of an affixin fragment containing the ILK-
binding CH2 domain inhibits initial spreading of the cells
(Yamaji et al., 2001). However, despite extensive efforts a
direct interaction between affixin–
 
 
 
-parvin and actin has
not been detected in vitro (Yamaji et al., 2001). Finally, ILK
can interact with the 
 
 
 
1 integrin cytoplasmic domain and
thereby could be potentially linked to the actin filaments
through other actin- and 
 
 
 
1 integrin–binding proteins such
as talin. It is worth noting that an interaction between
 
Drosophila
 
 ILK and the cytoplasmic domain of integrin 
 
 
 
PS
 
was not detected in yeast two-hybrid analyses (Zervas et al.,
2001). Consistent with this, 
 
Drosophila
 
 ILK is localized nor-
mally to muscle attachment sites in the absence of the 
 
 
 
PS
 
integrin (Zervas et al., 2001). However, in 
 
C. elegans 
 
inte-
grin is required for the proper localization of ILK (Mackin-
non, A.C., and B.D. Williams. 2000. 40th American Soci-
ety for Cell Biology Annual Meeting. 2664 [Abstr.]),
suggesting a connection between integrin and ILK in this or-
ganism.
The multiple interactions between ILK and the actin cy-
toskeleton have at least two important implications. First, it
could allow cells to modulate the physical strength of the
connection at the cell matrix contact sites. Second, it could
facilitate signal transduction and regulation through the cell
matrix contact sites. In addition to binding to ILK through
the LIM1 domain, PINCH can interact with Nck-2 (also
known as Nck
 
 
 
 or Grb4), an adaptor protein containing
three Src homology (SH)3 domains and one SH2 domain,
through the LIM4 domain (Tu et al., 1998) (Fig. 1). In
turn, Nck-2 could potentially help to bring other compo-
nents of the growth factor and small GTPase signaling path-
ways into proximity of the adhesion sites through interac-
tions mediated by the SH2 and SH3 domains.
 
Signaling role of ILK
 
ILK has a low basal kinase activity, which is stimulated tran-
siently by cell–ECM interactions and by certain growth fac-
tors (Dedhar, 2000). The activity is stimulated in a phospha-
tidylinositol (PI) 3-kinase–dependent manner and likely
 
Table I. 
 
ILK-binding proteins
Binding protein ILK-binding site Target on ILK Detection
 
a
 
Transmembrane receptors
 
(1) 
 
 
 
1 integrins 
 
 
 
1 cytoplasmic domain Kinase domain 2-hybrid, co-IP (Hannigan et al., 1996)
(2) 
 
 
 
3 integrins Not determined Not determined Co-IP (Hannigan et al., 1996)
 
Adaptor proteins
 
(1) PINCH LIM1  ANK domain Co-IP (Hannigan et al., 1996), ELISA (Tu et al., 1999)
(2) CH-ILKBP CH2 Kinase domain 2-hybrid, co-IP, pull-down (Tu et al., 2001)
(3) Affixin CH2 Kinase domain 2-hybrid, co-IP (Yamaji et al., 2001)
(4) Paxillin LD1 Kinase domain Co-IP, pull-down (Nikolopoulos and Turner, 2001)
 
Catalytic proteins
 
(1) ILKAP Not determined ANK-PH domains 2-hybrid, co-IP (Leung-Hagesteijn et al., 2001)
(2) PKB/Akt Not determined Kinase domain Co-IP (Persad et al., 2001a)
(3) PDK-1 Not determined Not determined Co-IP (Persad et al., 2001a)
 
a
 
2-hybrid, yeast two-hybrid binding assays; co-IP, coimmunoprecipitation; pull-down, GST fusion protein pull-down assay. 
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involves binding of the phosphoinositide phospholipid prod-
uct of PI 3-kinase, PI 3,4,5-triphosphate, to the PH-like do-
main of ILK (Dedhar, 2000). ILK activity is regulated nega-
tively by two phosphatases: PTEN, a tumor suppressor lipid
phosphatase, which dephosphorylates PI 3,4,5-triphosphate
to PI 4,5-bisphosphate, and a PP2C protein phosphatase,
ILKAP (Morimoto et al., 2000; Persad et al., 2000; 2001b;
Leung-Hagesteijn et al., 2001). ILK activity is activated con-
stitutively in PTEN-null tumor cells (Persad et al., 2000,
2001b). Both PI 3,4,5-triphosphate binding and (auto)phos-
phorylation appear to be crucial for ILK activation, since mu-
tations in the PH domain (Arg 211) or in the activation loop
serine (ser) 343 render the kinase inactive and unable to phos-
phorylate protein kinase B (PKB)/Akt (Persad et al., 2001a).
Despite having a somewhat unusual kinase catalytic do-
main (Dedhar et al., 1999; Lynch et al., 1999; Dedhar,
2000), ILK has been shown recently to directly phosphory-
late proteins such as PKB (PKB/Akt) on ser 473 (Persad et
al., 2001a), glycogen synthase kinase 3 (GSK-3) on ser 9
(Persad et al., 2001b), myosin light chain (MLC) on ser 18/
thr 19 (Deng et al., 2001), and ILK-binding protein affixin
(Yamaji et al., 2001). In addition, ILK can phosphorylate
the cytoplasmic domain of 
 
 
 
1 integrin subunit in vitro
(Hannigan et al., 1996), although whether this occurs in in-
tact cells is not clear. On the other hand, Lynch et al. (1999)
have suggested that ILK regulates the phosphorylation of
PKB/Akt on ser 473 indirectly. This suggestion was based
on their inability to detect kinase activity in ILK immuno-
precipitates and on the reversal of a dominant negative form
of ILK to wild type by mutation of ser 343 to aspartic acid.
However, more recent work by Persad et al. (2001a) has
shown that a similar mutation in another dominant negative
form of ILK does not cause this reversal and that ser 343 is
critical for ILK kinase activity. Thus, the issue of whether
ILK has kinase activity remains controversial, although the
recent demonstration of ILK as a kinase (Deng et al., 2001;
Persad et al., 2001a) seems to tip the balance in favor of ILK
being a bona fide serine/threonine protein kinase. However,
it is also likely that certain functions of ILK may not require
its kinase activity. This is apparent from the suggestion that
the regulation of integrin–actin cytoskeleton interaction by
ILK in 
 
Drosophila
 
 may not require kinase activity (Zervas et
al., 2001), although it should be pointed out that the muta-
tion in the ILK kinase domain on which this conclusion was
based results in the retention of substantial amount of resid-
ual ILK activity (Persad et al., 2001a; Yamaji et al., 2001).
The role of ILK in the stimulation of various signaling
pathways (Fig. 1 B) has been demonstrated by analyzing ILK
activity in cells stimulated by ECM or growth factors and in
cells overexpressing ILK. Overexpression of ILK in epithelial
cells resulted in an increased phosphorylation of PKB/Akt
and GSK-3 (Lynch et al., 1999; Dedhar, 2000), activating
the former and inhibiting the latter. The hallmarks of over-
expressing ILK in normal epithelial cells is the loss of cell–
cell adhesion, due to the downregulation of E-cadherin ex-
pression, and nuclear translocation of 
 
 
 
-catenin (Dedhar,
2000; Somasiri et al., 2001). The downregulation of E-cad-
herin expression may involve ILK-mediated activation of the
E-cadherin repressor Snail (Tan et al., 2001), and nuclear
 
 
 
-catenin activation may involve ILK-mediated inhibition
 
of GSK-3 activity, resulting in 
 
 
 
-catenin stabilization (Persad
et al., 2001b). The inhibition of GSK-3 by ILK also results in
the activation of the transcription factor AP-1 (Dedhar,
2000), which along with 
 
 
 
-catenin/Tcf and the transcription
factor CREB may also be responsible for ILK-mediated up-
regulation of cyclin D1 expression (D’Amico et al., 2000).
ILK-induced AP-1 activity also results in the stimulation of
expression of matrix metalloproteinase-9 (Troussard et al.,
2000). It should be pointed out that these readily demon-
strated signaling functions of ILK in mammalian cells appear
not to be conserved in 
 
Drosophila
 
, since inactivating muta-
tion of 
 
Drosophila 
 
ILK does not appear to affect PKB/Akt,
GSK-3, or 
 
 
 
-catenin pathways (Zervas et al., 2001).
One of the consequences of constitutive ILK activation, or
overexpression, in mammalian cells is suppression of apop-
tosis and anoikis (Attwell et al., 2000; Persad et al., 2000).
Both of these effects involve ILK-mediated activation of
PKB/Akt and suppression of activation of caspase 3. The
central role of ILK in these pathways can be inferred from
experiments in which inhibiting ILK with a dominant nega-
tive form of ILK or by a pharmacological inhibitor of ILK
induced apoptosis in cells in which PKB/Akt is activated
constitutively (Persad et al., 2000). It is interesting that
mammary gland tumors arise in ILK transgenic mice, and
the tumor tissues exhibit many of the hallmarks of ILK over-
expression in tissue culture cells, namely phosphorylation of
PKB/Akt and GSK-3 but also downregulation of expression
of E-cadherin and phosphorylation and activation of extra-
cellular signal–regulated kinase (Erk) (West et al., 2001).
ILK also appears to regulate muscle differentiation by acti-
vating Erk, which suppresses transcription factors required
for myogenic differentiation (Huang et al., 2000). The sig-
naling pathway involved in the ILK-mediated Erk activation
remains to be determined.
Therefore, it is apparent that ILK can control the activities
of key signaling pathways, leading to the stimulation of
downstream effector kinases and transcription factors, which
either activate or repress the expression of genes encoding
proteins involved in the regulation of cell survival, the cell
cycle, cell adhesion, and ECM modification (Fig. 1 B). In
addition, ILK may also be involved in the regulation of cell
migration, cell motility, and contractility by directly phos-
phorylating proteins such as MLC (Deng et al., 2001) and
affixin (Yamaji et al., 2001). The phosphorylation of the lat-
ter may also affect early stages of cell spreading by modulat-
ing the interaction of affixin with actin and ILK (Yamaji et
al., 2001). Although not demonstrated yet, it is likely that
ILK can also phosphorylate CH-ILKBP, since affixin and
CH-LIKBP share significant sequence similarity and appear
to bind to ILK via similar domains. ILK may also modulate
adhesion and spreading by directly or indirectly regulating
the phosphorylation of the 
 
 
 
1 integrin cytoplasmic domain,
since serine phosphorylation of this subunit has been impli-
cated in integrin-mediated regulation of cell adhesion,
spreading, and formation of focal adhesion plaques (Mul-
rooney et al., 2000).
 
Conclusion
 
The combination of genetic, biochemical, and cell biological
studies demonstrates that ILK plays a central role in connect- 
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ing integrins to actin filaments, and it also plays crucial roles
in the regulation of cell survival, cell proliferation, and cell–
cell adhesion. In addition, in its ability to phosphorylate my-
osin in smooth muscle cells ILK may also have an important
role in regulating smooth muscle contraction and cell motil-
ity in nonmuscle cells. Thus, ILK provides a molecular scaf-
fold for the assembly of proteins such as PINCH, CH-
ILKBP, affixin, and paxillin, which bridge the ECM and
growth factors via integrins and growth factor receptors to
the actin cytoskeleton (Fig. 1 A). ILK also couples integrins
and growth factor receptors to downstream signaling com-
ponents (Fig. 1 B). It should be pointed out that these two
functions of ILK need not be mutually exclusive, since it is
entirely possible that the scaffold function of ILK is required
for its signaling function. This is indeed the case for
PINCH, which has the potential, via Nck-2, to couple ILK
to growth factor receptors. In addition, the recent demon-
stration that PKB/Akt and PI 3-kinase–dependent kinase
(PDK)-1, a key regulator of PKB/Akt, can complex with
ILK also suggests a role for ILK in the compartmentalization
of signaling components. Furthermore, since many proteins
appear to bind to ILK within the kinase catalytic domain it is
possible that the activity of ILK and its signaling properties
are also regulated by such interactions. The challenge for the
future is going to be the dissection of the roles of the various
ILK interactions in cell anchorage, migration, and signaling.
Finally, dysregulation of ILK activity and/or expression ap-
pears to play important roles in certain disease states. Overex-
pression, or constitutive activation of ILK, due to inactivating
mutations in tumor suppressors such as PTEN or APC lead
to oncogenic transformation of cell lines and tumor forma-
tion in transgenic mouse models (Dedhar, 2000; West et al.,
2001). In addition, ILK expression and activity are upregu-
lated in Ewings sarcomas, advanced prostate cancers (Graff et
al., 2001), and colonic poyposis and colorectal cancers (Ma-
rotta et al., 2001). ILK has also been demonstrated recently to
be upregulated in the kidney glomeruli in patients with dia-
betic nephropathy (Guo et al., 2001), from children with
congenital nephrotic syndrome, and in kidney podocytes
from two murine models of proteinuria (Kretzler et al., 2001).
Given the central role of ILK in connecting integrins to
the actin cytoskeleton and regulation of cell growth, dysreg-
ulation of ILK is likely to have much wider implications in
many developmental and somatic diseases, underscoring the
need to understand fully the mechanism of its regulation
and activation.
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